| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Amber M Muehlmann | Q79260776 |
| P2093 | author name string | Elliott Richelson | |
| Paul Fredrickson | |||
| Mona M Boules | |||
| P2860 | cites work | Striatal injection of neurotensin increases tyrosine hydroxylase mRNA in substantia nigra | Q48592445 |
| Changes in the developmental trajectories of striatum in autism | Q48628075 | ||
| Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems | Q48655143 | ||
| Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity | Q48769011 | ||
| DA2/NT receptor balance in the mesostriatal and mesolimbocortical systems after chronic treatment with typical and atypical neuroleptic drugs | Q48860423 | ||
| Striatal volume on magnetic resonance imaging and repetitive behaviors in autism | Q48866759 | ||
| Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens. | Q48956993 | ||
| Neurotensin receptors are located on dopamine-containing neurones in rat midbrain | Q49134437 | ||
| Antipsychotic Medications: Clinical Use and Effectiveness | Q49154082 | ||
| Quantitative magnetic resonance imaging in Rett syndrome | Q50306365 | ||
| Metabotropic glutamate subtype 5 receptors modulate fear-conditioning induced enhancement of prepulse inhibition in rats | Q50461612 | ||
| Neurodevelopmental effects of the FMR-1 full mutation in humans. | Q52019051 | ||
| mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. | Q52564964 | ||
| Effects of D-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. | Q53998608 | ||
| Neurotensin increases endogenous glutamate release in rat cortical slices | Q62965080 | ||
| The dopamine hypothesis of schizophrenia: version III--the final common pathway | Q22242827 | ||
| Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor | Q24314254 | ||
| Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain | Q24320397 | ||
| Neurotensin receptor antagonist administered during cocaine withdrawal decreases locomotor sensitization and conditioned place preference | Q24634249 | ||
| Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. | Q24648260 | ||
| Comparing protein abundance and mRNA expression levels on a genomic scale | Q24682985 | ||
| Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling | Q27023967 | ||
| Gastrointestinal flora and gastrointestinal status in children with autism – comparisons to typical children and correlation with autism severity | Q27496651 | ||
| Neurotensin and neurotensin receptors | Q28138527 | ||
| Sortilin/neurotensin receptor-3: a new tool to investigate neurotensin signaling and cellular trafficking? | Q28205453 | ||
| Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia | Q28211177 | ||
| Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice | Q28214803 | ||
| Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial | Q28244389 | ||
| Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia | Q28250711 | ||
| Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine | Q28259049 | ||
| A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia | Q28263502 | ||
| Molecular cloning of a levocabastine-sensitive neurotensin binding site | Q28280443 | ||
| Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study | Q28280894 | ||
| Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders | Q28302151 | ||
| Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs | Q68300523 | ||
| Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values | Q69374550 | ||
| Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome | Q69380133 | ||
| Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat | Q69597355 | ||
| Effects of anticholinergic drugs on regional brain neurotensin concentrations | Q69720932 | ||
| Changes in the limbic neurotensin systems induced by dopaminergic drugs | Q69929296 | ||
| Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients | Q70122278 | ||
| Neurotensin stimulates formation of cyclic GMP in murine neuroblastoma clone N1E-115 | Q70218225 | ||
| Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra | Q70472255 | ||
| Isolation, structure and biologic activity of chicken intestinal neurotensin | Q70807049 | ||
| Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study | Q71370125 | ||
| Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats | Q71490894 | ||
| Effects of neurotensin in a rodent model of tardive dyskinesia | Q71760128 | ||
| Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat | Q72237073 | ||
| Neurotensin: perchance an endogenous neuroleptic? | Q72431662 | ||
| Increase of neurotensin content elicited by neuroleptics in nucleus accumbens | Q72440394 | ||
| Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment | Q72533931 | ||
| Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol | Q73455068 | ||
| Network interactions in schizophrenia - therapeutic implications | Q73553195 | ||
| Neurotensin inhibits neuronal Na+,K+-ATPase activity through high affinity peptide receptor | Q73816029 | ||
| Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization | Q73964518 | ||
| Effects of acute and subchronic administration of typical and atypical antipsychotic drugs on the neurotensin system of the rat brain | Q74326638 | ||
| Schizophrenia | Q79226206 | ||
| Addressing side effects from antipsychotic treatment in schizophrenia | Q83553940 | ||
| Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease | Q36586033 | ||
| Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides | Q36797523 | ||
| Brain levels of neuropeptides in human chronic methamphetamine users | Q36852952 | ||
| Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist | Q36894729 | ||
| Dopamine hypothesis of schizophrenia: making sense of it all. | Q36946141 | ||
| Evidence for three subtypes of repetitive behavior in autism that differ in familiality and association with other symptoms | Q37007579 | ||
| Neurotensin in the ventral pallidum increases extracellular gamma-aminobutyric acid and differentially affects cue- and cocaine-primed reinstatement | Q37168720 | ||
| Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis | Q37208845 | ||
| Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties | Q43786454 | ||
| Relapse to cocaine- and heroin-seeking behavior mediated by dopamine D2 receptors is time-dependent and associated with behavioral sensitization | Q43829041 | ||
| Chronic blockade of neurotensin receptors strongly reduces sensitized, but not acute, behavioral response to D-amphetamine | Q43829052 | ||
| The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. | Q43846382 | ||
| Effects of haloperidol and risperidone on neurotensin levels in brain regions and neurotensin efflux in the ventral striatum of the rat. | Q43942962 | ||
| Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: counteraction by a NTR1-like receptor antagonist. | Q43984667 | ||
| Effects of neurotensin receptor antagonism on latent inhibition in Sprague-Dawley rats | Q44001122 | ||
| d-Amphetamine-induced increase in neurotensin and neuropeptide Y outflow in the ventral striatum is mediated via stimulation of dopamine D1 and D2/3 receptors | Q44059836 | ||
| NMDA-induced phosphorylation and regulation of mGluR5. | Q44063851 | ||
| Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens | Q44192962 | ||
| Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine | Q44237544 | ||
| Blockade of nicotine-induced locomotor sensitization by a novel neurotensin analog in rats | Q44260116 | ||
| The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity | Q44278062 | ||
| Striatal opioid peptide content in an animal model of spontaneous stereotypic behavior | Q44347720 | ||
| A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist | Q44374765 | ||
| Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors | Q44463966 | ||
| Environmental enrichment: effects on stereotyped behavior and dendritic morphology | Q44470576 | ||
| Novel neurotensin analog blocks the initiation and expression of nicotine-induced locomotor sensitization | Q44506396 | ||
| Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice | Q44654536 | ||
| Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects | Q44754229 | ||
| Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release | Q44793030 | ||
| Neurotensin agonists block the prepulse inhibition deficits produced by a 5-HT2A and an alpha1 agonist | Q44859861 | ||
| Neuroscience of addiction | Q44880443 | ||
| Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain | Q44960726 | ||
| Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2. | Q45054330 | ||
| Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists | Q45248983 | ||
| NT69L blocks ethanol-induced increase of dopamine and glutamate levels in striatum of mouse | Q45306766 | ||
| A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats | Q45942528 | ||
| The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists. | Q45999986 | ||
| Intra-accumbens shell injections of SR48692 enhanced cocaine self-administration intake in rats exposed to an environmentally-elicited reinstatement paradigm. | Q46011989 | ||
| Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms. | Q46036064 | ||
| Impaired anorectic effect of leptin in neurotensin receptor 1-deficient mice | Q46474637 | ||
| Effects of 5 daily injections of the neurotensin-mimetic NT69L on the expression of neurotensin receptors in rat brain | Q46476165 | ||
| Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation | Q46507878 | ||
| Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist | Q46510974 | ||
| The effects of intra-accumbens neurotensin on sensorimotor gating | Q46654286 | ||
| Metabotropic glutamate receptor 5 binding and protein expression in schizophrenia and following antipsychotic drug treatment | Q46793534 | ||
| Pro-dopamine effects of neurotensin on sensorimotor gating deficits | Q46891399 | ||
| A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents | Q47239028 | ||
| Neurontensin studies in alcohol naive, preferring and non-preferring rats | Q48147693 | ||
| CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates | Q48153202 | ||
| Fronto-striatal dysfunction and potential compensatory mechanisms in male adolescents with fragile X syndrome | Q48201398 | ||
| Effects of neurotensin gene knockout in mice on the behavioral effects of cocaine. | Q48250562 | ||
| Development of an autism severity score for mice using Nlgn4 null mutants as a construct-valid model of heritable monogenic autism | Q48279049 | ||
| Widespread expression in adult rat forebrain of mRNA encoding high-affinity neurotensin receptor | Q48323707 | ||
| Atypical neuroleptic-like behavioral effects of neurotensin | Q48385983 | ||
| The striatal neurotensin receptor modulates striatal and pallidal glutamate and GABA release: functional evidence for a pallidal glutamate-GABA interaction via the pallidal-subthalamic nucleus loop. | Q48407590 | ||
| Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport | Q48452271 | ||
| Craniocerebral magnetic resonance imaging measurement and findings in Lesch-Nyhan syndrome | Q48482977 | ||
| ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models | Q28303494 | ||
| Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP | Q28511269 | ||
| Distribution of NTS3 receptor/sortilin mRNA and protein in the rat central nervous system | Q28567151 | ||
| Sustained neurotensin exposure promotes cell surface recruitment of NTS2 receptors | Q28574798 | ||
| Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors | Q28579384 | ||
| Neurotensin depolarizes globus pallidus neurons in rats via neurotensin type-1 receptor | Q28582495 | ||
| Implications of normal brain development for the pathogenesis of schizophrenia | Q29618740 | ||
| Recent advances in the phencyclidine model of schizophrenia | Q29618917 | ||
| Diverse roles of neurotensin agonists in the central nervous system | Q30456105 | ||
| Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice | Q30475347 | ||
| Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: a possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia | Q30475349 | ||
| Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance | Q30477036 | ||
| NT79: A novel neurotensin analog with selective behavioral effects | Q30477584 | ||
| Sensorimotor gating in neurotensin-1 receptor null mice | Q30477911 | ||
| Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. | Q31841102 | ||
| Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain. | Q32065524 | ||
| Regional gray matter volumetric changes in autism associated with social and repetitive behavior symptoms | Q33266464 | ||
| Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function | Q33493599 | ||
| Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder | Q33496741 | ||
| D1 dopamine receptor-mediated LTP at GABA synapses encodes motivation to self-administer cocaine in rats | Q33573158 | ||
| Neurotensin receptor type 1 regulates ethanol intoxication and consumption in mice | Q33695438 | ||
| Does neurotensin mediate the effects of antipsychotic drugs? | Q33704191 | ||
| Indirect basal ganglia pathway mediation of repetitive behavior: attenuation by adenosine receptor agonists | Q33749330 | ||
| Neurotransmitter interactions in schizophrenia--therapeutic implications | Q33782626 | ||
| NMDA receptor hypofunction model of schizophrenia | Q33813143 | ||
| Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia | Q34090017 | ||
| Neurotensin is increased in serum of young children with autistic disorder | Q34114124 | ||
| Catching up on schizophrenia: natural history and neurobiology | Q34122141 | ||
| Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia | Q34127175 | ||
| Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs | Q34192438 | ||
| Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling. | Q34228069 | ||
| Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence | Q34235541 | ||
| The effects of neuropeptides on discrete-trial conditioned avoidance responding | Q34249385 | ||
| Phencyclidine | Q34280939 | ||
| Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization | Q34382515 | ||
| The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance | Q37370136 | ||
| Elevated immune response in the brain of autistic patients | Q37405256 | ||
| The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature | Q37442045 | ||
| Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists | Q37775612 | ||
| The role of neurotensin in physiologic and pathologic processes | Q37814885 | ||
| Pharmacological management of acute and persistent aggression in forensic psychiatry settings | Q37963568 | ||
| SHANK3 as an autism spectrum disorder-associated gene | Q38023003 | ||
| Update on typical and atypical antipsychotic drugs | Q38047415 | ||
| Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. | Q38068703 | ||
| Feeding problems and nutrient intake in children with autism spectrum disorders: a meta-analysis and comprehensive review of the literature | Q38078293 | ||
| Drug discovery for autism spectrum disorder: challenges and opportunities | Q38147860 | ||
| Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin | Q39109781 | ||
| Neurotensin and the mesocorticolimbic dopamine system | Q39298444 | ||
| The current status of the dopamine hypothesis of schizophrenia | Q39577491 | ||
| The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine | Q40576758 | ||
| Repetitive and self-injurious behaviors: associations with caudate volume in autism and fragile X syndrome | Q40630474 | ||
| Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients | Q40808959 | ||
| Mechanisms of regulation of neurotensin receptors | Q41006768 | ||
| The dopamine hypothesis of schizophrenia: focus on the dopamine receptor | Q41076667 | ||
| Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment | Q41089455 | ||
| Further studies on the modulation of regional brain neurotensin concentrations by antipsychotic drugs: focus on haloperidol and BMY 14802 | Q41126916 | ||
| Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24. | Q41150864 | ||
| Neurotensin: central nervous system effects of a hypothalamic peptide | Q41279452 | ||
| Reduced CSF neurotensin concentration in drug-free schizophrenic patients | Q41393188 | ||
| Role of signal transduction systems in neurotensin receptor down-regulation induced by agonist in murine neuroblastoma clone N1E-115 cells. | Q41524362 | ||
| The rat neurotensin receptor expressed in Chinese hamster ovary cells mediates the release of inositol phosphates | Q41597301 | ||
| Structure and functional expression of the cloned rat neurotensin receptor | Q41733457 | ||
| Emerging roles for novel antipsychotic medications in the treatment of schizophrenia | Q41743497 | ||
| Autism-related behavioral abnormalities in synapsin knockout mice. | Q41845734 | ||
| The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex | Q41879435 | ||
| The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition | Q42167718 | ||
| Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation | Q42246826 | ||
| Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies | Q42254857 | ||
| Targeting neurotensin as a potential novel approach for the treatment of autism | Q42407155 | ||
| Dopamine regulation of extracellular glutamate in the nucleus accumbens | Q42442290 | ||
| Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum | Q42459207 | ||
| The cloned neurotensin receptor mediates cyclic GMP formation when coexpressed with nitric oxide synthase cDNA. | Q42476325 | ||
| Neurotensin regulates cortical glutamate transmission by modulating N-methyl-D-aspartate receptor functional activity: an in vivo microdialysis study | Q42489739 | ||
| Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens | Q42492206 | ||
| Rapid desensitization of agonist-induced calcium mobilization in transfected PC12 cells expressing the rat neurotensin receptor | Q42504605 | ||
| Development of repetitive behavior in a mouse model: roles of indirect and striosomal basal ganglia pathways | Q42744117 | ||
| The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats | Q42750368 | ||
| Adolescent chronic apomorphine treatment impairs latent inhibition and reduces prefrontal cortex mGluR5 receptor expression in adult rats | Q42877122 | ||
| Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole | Q42961384 | ||
| The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801. | Q43108258 | ||
| Role of neurotensin receptor 1 in the regulation of food intake by neuromedins and neuromedin-related peptides. | Q43254766 | ||
| Nicotine induced behavioral locomotor sensitization | Q43550716 | ||
| Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia | Q43698345 | ||
| Once weekly administration of nicotine produces long-lasting locomotor sensitization in rats via a nicotinic receptor-mediated mechanism | Q43703205 | ||
| A novel neurotensin analog blocks cocaine- and D-amphetamine-induced hyperactivity | Q43722020 | ||
| Evidence that mesoaccumbens dopamine and locomotor responses to nicotine in the rat are influenced by pretreatment dose and strain | Q43783816 | ||
| Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children | Q34404824 | ||
| CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder | Q34431402 | ||
| Neurotensin and dopamine interactions. | Q34457618 | ||
| The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs | Q34463402 | ||
| Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings | Q34479691 | ||
| Glutamatergic mechanisms in schizophrenia | Q34504043 | ||
| Neurotensin selectively facilitates glutamatergic transmission in globus pallidus | Q34543683 | ||
| New insights into the mechanism of action of amphetamines | Q34599276 | ||
| Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1). | Q34645829 | ||
| Antipsychotic drugs for first-episode schizophrenia: a comparative review | Q34659096 | ||
| Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2 | Q34680977 | ||
| Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. | Q34691646 | ||
| Effect of methamphetamine self-administration on neurotensin systems of the basal ganglia | Q34702359 | ||
| Mortality in a cohort of patients with schizophrenia: a record linkage study | Q34804832 | ||
| Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? | Q35014255 | ||
| Neurotensin agonists: possible drugs for treatment of psychostimulant abuse | Q35152140 | ||
| Distribution of neurotensin receptors in mammalian brain. What it is telling us about its interactions with other neurotransmitter systems | Q35273394 | ||
| Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies | Q35273406 | ||
| Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin | Q35273456 | ||
| Role of Gastrointestinal Hormones in the Proliferation of Normal and Neoplastic Tissues | Q35564914 | ||
| Animal behavior models of the mechanisms underlying antipsychotic atypicality | Q35595230 | ||
| Neurotensin, schizophrenia, and antipsychotic drug action | Q35684732 | ||
| The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. | Q36084926 | ||
| Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals | Q36094323 | ||
| Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics | Q36244962 | ||
| Further characterization of repetitive behavior in C58 mice: developmental trajectory and effects of environmental enrichment | Q36251296 | ||
| Theoretical insights into the mechanism of action of atypical antipsychotics. | Q36386834 | ||
| Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition | Q36401781 | ||
| Current schizophrenia drugs: efficacy and side effects | Q36488206 | ||
| The role of neurotensin in central nervous system pathophysiology: what is the evidence? | Q36544566 | ||
| Functional roles of the NTS2 and NTS3 receptors. | Q36548883 | ||
| Bioactive analogs of neurotensin: focus on CNS effects | Q36553978 | ||
| Neurotensin: role in psychiatric and neurological diseases. | Q36557460 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | pathophysiology | Q1135939 |
| P304 | page(s) | 125-153 | |
| P577 | publication date | 2014-06-13 | |
| P1433 | published in | Behavioral sciences (Basel, Switzerland) | Q27724027 |
| P1476 | title | Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders | |
| P478 | volume | 4 |
| Q35066670 | A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties |
| Q39033778 | Antipsychotic inductors of brain hypothermia and torpor-like states: perspectives of application |
| Q30356261 | Antipsychotic-like effects of a neurotensin receptor type 1 agonist. |
| Q55265773 | Determination of neurotensin projections to the ventral tegmental area in mice. |
| Q40776664 | Genome-wide association analysis of actigraphic sleep phenotypes in the LIFE Adult Study |
| Q49724180 | Identification of Neurotensin Receptor Expressing Cells in the Ventral Tegmental Area across the Lifespan. |
| Q38692971 | Neurotensin: A role in substance use disorder? |
| Q64102487 | Regional and Cellular Mapping of Sortilin Immunoreactivity in Adult Human Brain |
| Q47172685 | Role of central neurotensin in regulating feeding: Implications for the development and treatment of body weight disorders |
| Q64271114 | Screening pathways and hub genes involved in osteoclastogenesis by gene expression analysis of circulating monocytes based on Gibbs sampling |
| Q28828634 | Structure-guided development of heterodimer-selective GPCR ligands |
| Q36202656 | Synaptic Plasticity and Signal Transduction Gene Polymorphisms and Vulnerability to Drug Addictions in Populations of European or African Ancestry |
Search more.